Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Lou, Yun Feng ^a   Zou, Zheng Zhi ^b   Chen, Pin Jia ^a   Huang, Guo Bin ^c   Li, Bin ^a   Zheng, De Qing ^c   Yu, Xiu Rong ^a   Luo, Xiao Yong ^a  

^a ZHENGZHOU UNIVERSITY   (China)

^b SOUTH CHINA NORMAL UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CASPASE 3; GEFITINIB; INHIBITOR OF APOPTOSIS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; S6 KINASE; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS PROTEIN ASSOCIATED FACTOR 1; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; AZACITIDINE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; SIGNAL PEPTIDE; TARGET OF RAPAMYCIN KINASE; TUMOR PROTEIN; XAF1 PROTEIN, HUMAN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; COLON CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MIGRATION INHIBITION; ANALOGS AND DERIVATIVES; CELL SURVIVAL; COLON TUMOR; DNA METHYLATION; DOSE RESPONSE; DRUG EFFECTS; GENETICS; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AZACITIDINE; CELL LINE, TUMOR; CELL SURVIVAL; COLONIC NEOPLASMS; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASM PROTEINS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84902201210     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097719     Document Type: Article

References (53)

1. van Laarhoven HW, Punt CJ (2004) Systemic treatment of advanced colorectal carcinoma. Eur J Gastroenterol Hepatol 16: 283-289.
2. Troiani T, Lockerbie O, Morrow M, Ciardiello F, Eckhardt SG (2006) Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases. Mol Cancer Ther 5: 1883-1894. (Pubitemid 44323257)
3. Haraldsdottir S, Bekaii-Saab T (2013) Integrating anti-EGFR therapies in metastatic colorectal cancer. J Gastrointest Oncol 4: 285-298.
4. Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358: 1160-1174.
5. Aydin K, Okutur SK, Bozkurt M, Turkmen I, Namal E, et al. (2014) Effect of epidermal growth factor receptor status on the outcomes of patients with metastatic gastric cancer: A pilot study. Oncol Lett 7: 255-259.
6. Li X, Lu Y, Pan T, Fan Z (2010) Roles of autophagy in cetuximab-mediated cancer therapy against EGFR. Autophagy 6: 1066-1077.
7. Shen Y, Wang J, Han X, Yang H, Wang S, et al. (2013) Effectors of Epidermal Growth Factor Receptor Pathway: The Genetic Profiling ofKRAS, BRAF, PIK3CA, NRAS Mutations in Colorectal Cancer Characteristics and Personalized Medicine. PLoS One 8: e81628.
8. Huang S, Peet CR, Saker J, Li C, Armstrong EA, et al. (2013) Sym004, a Novel Anti-EGFR Antibody Mixture, Augments Radiation Response in Human Lung and Head and Neck Cancers. Mol Cancer Ther 12: 2772-2781.
9. Flageng MH, Knappskog S, Haynes BP, Lonning PE, Mellgren G (2013) Inverse regulation of EGFR/HER1 and HER2-4 in normal and malignant human breast tissue. PLoS One 8: e74618.
10. Hsiao SH, Liu HE, Lee HL, Lin CL, Chen WY, et al. (2013) Distinct Clinical Outcomes of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor (EGFR) Mutations Treated with EGFR Tyrosine Kinase Inhibitors: Non-Responders versus Responders. PLoS One 8: e83266.
11. Wheeler DL, Dunn EF, Harari PM (2010) Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 7: 493-507.
12. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, et al. (2012) Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483: 100-103.
13. Schneider BG, Peek RJ (2013) Gastric cancer prevention by demethylation. Cancer Prev Res (Phila) 6: 253-256.
14. Issa JP (2008) Cancer prevention: epigenetics steps up to the plate. Cancer Prev Res (Phila) 1: 219-222.
15. Azad N, Zahnow CA, Rudin CM, Baylin SB (2013) The future of epigenetic therapy in solid tumours-lessons from the past. Nat Rev Clin Oncol 10: 256-266.
16. Griffiths EA, Gore SD (2013) Epigenetic therapies in MDS and AML. Adv Exp Med Biol 754: 253-283.
17. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428. (Pubitemid 34587077)
18. Karahoca M, Momparler RL (2013) Pharmacokinetic and pharmacodynamic analysis of 5-aza-29-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy. Clin Epigenetics 5: 3.
19. Yang D, Torres CM, Bardhan K, Zimmerman M, McGaha TL, et al. (2012) Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo. J Immunol 188: 4441-4449.
20. Schwartz PA, Kuzmic P, Solowiej J, Bergqvist S, Bolanos B, et al. (2013) Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance. Proc Natl Acad Sci U S A.
21. Wang J, Guo J, Wu S, Feng H, Sun S, et al. (2012) Synergistic effects of nanosecond pulsed electric fields combined with low concentration of gemcitabine on human oral squamous cell carcinoma in vitro. PLoS One 7: e43213.
22. Zou Z, Yuan Z, Zhang Q, Long Z, Chen J, et al. (2012) Aurora kinase A inhibition-induced autophagy triggers drug resistance in breast cancer cells. Autophagy 8: 1798-1810.
23. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
24. Wu YC, Wang XJ, Yu L, Chan FK, Cheng AS, et al. (2012) Hydrogen sulfide lowers proliferation and induces protective autophagy in colon epithelial cells. PLoS One 7: e37572.
25. Wang J, Gu Q, Li M, Zhang W, Yang M, et al. (2009) Identification of XAF1 as a novel cell cycle regulator through modulating G(2)/M checkpoint and interaction with checkpoint kinase 1 in gastrointestinal cancer. Carcinogenesis 30: 1507-1516.
26. Byun DS, Cho K, Ryu BK, Lee MG, Kang MJ, et al. (2003) Hypermethylation of XIAP-associated factor 1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas. Cancer Res 63: 7068-7075. (Pubitemid 37413441)
27. Smith DL, Lamy A, Beaudenon-Huibregtse S, Sesboue R, Laosinchai-Wolf W, et al. (2014) A Multiplex Technology Platform for the Rapid Analysis of Clinically Actionable Genetic Alterations and Validation for BRAF p.V600E Detection in 1549 Cytologic and Histologic Specimens. Arch Pathol Lab Med 138: 371-378.
28. Luca AC, Mersch S, Deenen R, Schmidt S, Messner I, et al. (2013) Impact of the 3D microenvironment on phenotype, gene expression, and EGFR inhibition of colorectal cancer cell lines. PLoS One 8: e59689.
29. Giannopoulou E, Antonacopoulou A, Floratou K, Papavassiliou AG, Kalofonos HP (2009) Dual targeting of EGFR and HER-2 in colon cancer cell lines. Cancer Chemother Pharmacol 63: 973-981.
30. Correale P, Marra M, Remondo C, Migali C, Misso G, et al. (2010) Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC). Eur J Cancer 46: 1703-1711.
31. Braun AH, Stark K, Dirsch O, Hilger RA, Seeber S, et al. (2005) The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan. Anticancer Drugs 16: 1099-1108. (Pubitemid 41565775)
32. Jones HE, Gee JM, Barrow D, Tonge D, Holloway B, et al. (2006) Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells. Br J Cancer 95: 172-180. (Pubitemid 44050916)
33. Toda D, Ota T, Tsukuda K, Watanabe K, Fujiyama T, et al. (2006) Gefitinib decreases the synthesis of matrix metalloproteinase and the adhesion to extracellular matrix proteins of colon cancer cells. Anticancer Res 26: 129-134. (Pubitemid 43206069)
34. Wang LS, Kuo CT, Cho SJ, Seguin C, Siddiqui J, et al. (2013) Black raspberry-derived anthocyanins demethylate tumor suppressor genes through the inhibition of DNMT1 and DNMT3B in colon cancer cells. Nutr Cancer 65: 118-125.
35. Zeller C, Dai W, Steele NL, Siddiq A, Walley AJ, et al. (2012) Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene 31: 4567-4576.
36. Toker A (2008) mTOR and Akt signaling in cancer: SGK cycles in. Mol Cell 31: 6-8.
37. Carr TD, DiGiovanni J, Lynch CJ, Shantz LM (2012) Inhibition of mTOR suppresses UVB-induced keratinocyte proliferation and survival. Cancer Prev Res (Phila) 5: 1394-1404.
38. Kim DJ, Reddy K, Kim MO, Li Y, Nadas J, et al. (2011) (3-Chloroacetyl)-indole, a novel allosteric AKT inhibitor, suppresses colon cancer growth in vitro and in vivo. Cancer Prev Res (Phila) 4: 1842-1851.
39. Dan HC, Sun M, Kaneko S, Feldman RI, Nicosia SV, et al. (2004) Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem 279: 5405-5412. (Pubitemid 38220563)
40. Rajput S, Kumar BN, Sarkar S, Das S, Azab B, et al. (2013) Targeted apoptotic effects of thymoquinone and tamoxifen on XIAP mediated Akt regulation in breast cancer. PLoS One 8: e61342.
41. Yao J, Jia L, Khan N, Zheng QD, Moncrief A, et al. (2012) Caspase inhibition with XIAP as an adjunct to AAV vector gene-replacement therapy: improving efficacy and prolonging the treatment window. PLoS One 7: e37197.
42. Bariol C, Suter C, Cheong K, Ku SL, Meagher A, et al. (2003) The relationship between hypomethylation and CpG island methylation in colorectal neoplasia. Am J Pathol 162:1361-71. (Pubitemid 36350680)
43. Bender CM, Pao MM, Jones PA (1998) Inhibition of DNA methylation by 5- aza-2′-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res 58:95-101. (Pubitemid 28027723)
44. Chung SK, Lee MG, Ryu BK, Lee JH, Han J, et al. (2007) Frequent alteration of XAF1 in human colorectal cancers: implication for tumor cell resistance to apoptotic stresses. Gastroenterology 132: 2459-2477. (Pubitemid 46890872)
45. Yang XH, Feng ZE, Yan M, Hanada S, Zuo H, et al. (2012) XIAP is a predictor of cisplatin-based chemotherapy response and prognosis for patients with advanced head and neck cancer. PLoS One 7: e31601.
46. Liston P, Fong WG, Kelly NL, Toji S, Miyazaki T, et al. (2001) Identification of XAF1 as an antagonist of XIAP anti-Caspase activity. Nat Cell Biol 3: 128-133. (Pubitemid 32118365)
47. Fong WG, Liston P, Rajcan-Separovic E, St JM, Craig C, et al. (2000) Expression and genetic analysis of XIAP-associated factor 1 (XAF1) in cancer cell lines. Genomics 70: 113-122.
48. Byun DS, Cho K, Ryu BK, Lee MG, Kang MJ, et al. (2003) Hypermethylation of XIAP-associated factor 1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas. Cancer Res 63: 7068-7075. (Pubitemid 37413441)
49. Zou B, Chim CS, Zeng H, Leung SY, Yang Y, et al. (2006) Correlation between the single-site CpG methylation and expression silencing of the XAF1 gene in human gastric and colon cancers. Gastroenterology 131: 1835-1843. (Pubitemid 44958519)
50. Wang J, Peng Y, Sun YW, He H, Zhu S, et al. (2006) All-trans retinoic acid induces XAF1 expression through an interferon regulatory factor-1 element in colon cancer. Gastroenterology 130: 747-758. (Pubitemid 43374525)
51. Yang CH, Huang CJ, Yang CS, Chu YC, Cheng AL, et al. (2005) Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. Cancer Res 65: 6943-6949. (Pubitemid 41060734)
52. Degterev A, Hitomi J, Germscheid M, Ch'En IL, Korkina O, et al. (2008) Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol 4: 313-321. (Pubitemid 351550892)
53. Wang K, Li J, Degterev A, Hsu E, Yuan J, et al. (2007) Structure-activity relationship analysis of a novel necroptosis inhibitor, Necrostatin-5. Bioorg Med Chem Lett 17: 1455-1465. (Pubitemid 46240823)